Cartesian Therapeutics financials
$7.24+0.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $2.8M | $38.9M | $26.0M |
| Gross profit | $2.8M | $38.9M | $26.0M |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Operating income | -$143.4M | -$43.9M | -$86.4M |
| Net income | -$130.3M | -$77.4M | -$257.3M |
| Net margin | −4658.6% | −199.0% | −989.3% |
| Diluted EPS | $-5.02 | $-4.49 | $-49.76 |
| EBITDA | -$83.7M | -$35.2M | -$84.9M |
| Operating cash flow | -$73.9M | -$23.7M | -$51.2M |
| Free cash flow | -$79.4M | -$32.8M | -$51.4M |
| Diluted shares | 26.0M | 17.4M | 5.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $125.1M | $212.6M | $76.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $296.4M | $435.0M | $305.1M |
| Total liabilities | $422.7M | $441.8M | $444.7M |
| Shareholders' equity | -$126.2M | -$6.8M | -$436.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology